Personalized medicine improves the treatment of osteoarthritis of the knee

Experts point out that advances in precision medicine will cause important changes in the approach to patients with osteoarthritis in the next 10 years. Optimizing clinical data is essential for establishing tailored and individualized treatments, depending on the origin and evolution of knee osteoarthritis.

Progress in precision medicine in recent years, they have enabled more tailored strategies for each patient knee osteoarthritis, depending on the origin and time of evolution from illness. This makes it possible to predict their prognosis and adjust the treatment more precisely to each person.

That is one of the conclusions II SER course in personalized medicinecelebrated in a way virtualIn cooperation with Pfizerwhere various experts dealt with issues such as The contribution of new technologies in the field of healthcare.

As pointed out by Dr. Franjo Castrorheumatologist at Sagrad Cor University Hospital in Barcelona, “In the field of osteoarthritis, recent studies have shown that, through genotyping techniquesit is possible to identify patients who are in the early stages of the disease, but who have a increased risk of structural progression of knee osteoarthritis«.

Geriatricrea course SER Personalized medicine of knee osteoarthritis experts virtual session
The II SER courses on personalized medicine addressed issues such as progress in the prognosis of osteoarthritis of the knee

“In the field knee osteoarthritismanaged to describe combinations of biochemical markers in blood and urine which enable differentiate molecularly groups of patients at risk of disease progression versus those who are not. Another one has also been identified solid molecular which identifies a group of patients with systemic inflammationwith the possibility of opening new ones fields in drug trials that target inflammation and pain in osteoarthritis”emphasizes the specialist.

“The possibility for predict which patients will progress and which will not It will be a a paradigm shift in trial design with disease-modifying drugswhich act at the target level of cartilage and subchondral bone, since the possibility of testing on the most sensitive patients implies the possibility of improving results and efficiency, by achieving more effective therapy and in a shorter timeconcludes Dr. Castro.

Bad new discoveries with biomarkers will enable the description of subgroups of patients with rheumatic diseases in a more homogeneous way, which results maximizing treatment benefits and fewer side effects.

Bad progress in the convergence of omics, the big data clinical and machine learningbring us to a reality, in the next ten years, in which we can design a therapy exactly adapted to the individual patientsomething that is already happening in other areas of medicine, as explained in II SER course in personalized medicine.

The importance of data that can be reused and integrated

The latest recommendations in data management in research focus on the existence of data reusable and integrable with other data, in order to achieve the construction of large databases.

In this sense, Dr. Diego Benaventrheumatologist at La Paz University Hospital in Madrid, indicates that “way to achieving the promise of personalized medicinehow to get the right treatment, at the right time, for the right patient optimize the use of clinical data, adapt to new research methodologies e carry out conclusions study in everyday clinical practice».

geriatricrea knee osteoarthritis
Advances in precision medicine enable strategies that are more tailored to each knee osteoarthritis patient

Doctor Diego Benaventrheumatologist La Paz University Hospital in Madridstates that “the development of predictive models in rheumatic pathology based on precise artificial intelligence rheumatologists involved in studies to ask relevant research questions, support for data scientists Mr critically evaluate The results”.

II SER course in personalized medicine

The dialogue center of this new edition of the courses BE of personalized medicine, which had the help of the pharmaceutical company Pfizer, revolved around topics such as new technologies in biomarkers, Contribution of omics technologies to personalized medicine in autoimmune diseases Mr precision rheumatology in the clinicamong others.

Within this scenario, different experts contributed their knowledge and everyday experiences to achieve new steps in this sector. like a doctor Francis J Whiteprofessor of rheumatology at University of Coruna and from Rheumatology Service of the University Hospital Complex A Coruñawho claims that “essentially train in this field because it is the near future of medicine and rheumatology. Tomorrow’s patients are passing through the ability to predict the onset of diseasethe prognosis from them and know what they are the best treatments for everyonefrom individualized way«.

Leave a Comment